Hospital
South Shore University Hospital
South Shore University Hospital was paid $47.45M by Medicaid between Jan 2018 and Dec 2024, across 235 billing codes. Its largest line is 99283, emergency room visit (moderate) — 14% of everything it billed.
33Billing provider infoSOUTH SHORE UNIVERSITY HOSPITAL
BAY SHORE, NY 11706
BAY SHORE, NY 11706
33aNPI1457369381assigned 08/04/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$47.45M
24GClaims877,922
24DCodes billed235
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New York
Rank by total paid#32 of 231
Median peer was paid$561K
This provider vs. median85×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official CUSACK, MICHELE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 18,977 | $788K | |
| 2019 | 56,021 | $2.96M | |
| 2020 | 114,639 | $6.74M | |
| 2021 | 178,345 | $10.35M | |
| 2022 | 165,926 | $9.17M | |
| 2023 | 187,238 | $9.84M | |
| 2024incomplete | 156,776 | $7.60M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 38,395 | 36,347 | $6.63M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 11% | 44,009 | 12,144 | $5.30M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 32,025 | 30,149 | $5.20M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.9% | 16,578 | 15,192 | $2.78M |
| 36415 | Collection of venous blood by venipuncture | 4.0% | 123,914 | 50,566 | $1.92M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.9% | 6,786 | 6,501 | $1.85M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.5% | 9,547 | 9,220 | $1.64M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.4% | 5,680 | 5,498 | $1.61M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.7% | 1,830 | 1,819 | $1.26M |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.6% | 4,518 | 4,360 | $1.24M |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 2.6% | 1,811 | 1,772 | $1.23M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.4% | 8,541 | 8,059 | $1.14M |
223 more codes
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 2.3% | 16,637 | $1.10M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2.2% | 7,579 | $1.03M |
| G0378 | Hospital observation service, per hour | 2.2% | 4,246 | $1.02M |
| 80053 | Comprehensive metabolic panel | 2.1% | 39,831 | $1.00M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.2% | 691 | $571K |
| 59025 | Fetal non-stress test | 1.1% | 2,461 | $526K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 8,615 | $525K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,609 | $458K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 4,891 | $447K |
| 95800 | <1% | 1,019 | $438K | |
| 95806 | <1% | 424 | $386K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 8,941 | $376K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 429 | $358K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,231 | $333K |
| 12001 | <1% | 680 | $332K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,755 | $308K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 18,252 | $290K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 986 | $237K |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 251 | $227K |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 11,973 | $219K |
| 86850 | <1% | 6,487 | $218K | |
| 97161 | <1% | 2,075 | $208K | |
| 86901 | <1% | 6,478 | $204K | |
| 86900 | <1% | 6,481 | $202K | |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 469 | $201K |
| 0225U | <1% | 9,088 | $182K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 11,391 | $162K |
| 93970 | <1% | 236 | $157K | |
| 12011 | <1% | 308 | $155K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,838 | $154K |
| 88342 | <1% | 1,955 | $143K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,130 | $141K |
| 76801 | <1% | 1,357 | $139K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,128 | $126K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,031 | $126K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 4,247 | $124K |
| 97162 | <1% | 1,005 | $114K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,602 | $108K |
| 83880 | <1% | 3,343 | $103K | |
| 64483 | <1% | 120 | $96K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,301 | $82K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,178 | $77K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 8,068 | $74K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 356 | $67K |
| 70498 | <1% | 240 | $65K | |
| 62323 | <1% | 102 | $64K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 197 | $64K |
| J3490 | Unclassified drugs | <1% | 8,680 | $63K |
| 76000 | <1% | 1,690 | $60K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 25,215 | $59K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 327 | $55K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 14,890 | $52K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 630 | $51K |
| 82803 | <1% | 2,315 | $48K | |
| C1769 | Guide wire | <1% | 385 | $43K |
| 90715 | <1% | 1,503 | $42K | |
| 87631 | <1% | 611 | $41K | |
| 12002 | <1% | 81 | $41K | |
| 93971 | <1% | 619 | $40K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,338 | $38K |
| 97165 | <1% | 300 | $37K | |
| 77002 | <1% | 86 | $36K | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 1,652 | $36K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,309 | $36K |
| 85610 | <1% | 9,152 | $35K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,840 | $35K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 43 | $35K |
| 97116 | <1% | 838 | $35K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 146 | $35K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 37 | $33K |
| 62321 | <1% | 48 | $33K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,919 | $33K |
| 20610 | <1% | 86 | $32K | |
| 86703 | <1% | 2,266 | $32K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 3,706 | $31K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 953 | $30K |
| 29125 | <1% | 122 | $30K | |
| 96376 | <1% | 2,375 | $27K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,468 | $27K |
| 10060 | <1% | 71 | $26K | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 83 | $25K |
| 76830 | Ultrasound, transvaginal | <1% | 1,340 | $25K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 331 | $23K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,966 | $21K |
| 84702 | <1% | 15,580 | $21K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 82 | $18K |
| 85027 | <1% | 12,612 | $16K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 31,482 | $14K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 243 | $14K |
| 71045 | Radiologic examination, chest; single view | <1% | 9,862 | $14K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,176 | $14K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 172 | $13K |
| 81025 | <1% | 4,012 | $13K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 112 | $13K |
| 70486 | <1% | 343 | $13K | |
| G0400 | Home sleep test (hst) with type iv portable monitor, unattended; minimum of 3 channels | <1% | 13 | $12K |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 46 | $12K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,371 | $11K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 245 | $11K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 758 | $11K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 37 | $11K |
| 72131 | <1% | 68 | $11K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,426 | $11K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,986 | $10K |
| 64493 | <1% | 12 | $10K | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,778 | $10K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 925 | $10K |
| 85730 | <1% | 9,441 | $10K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 33 | $9K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 28 | $9K |
| 77003 | <1% | 658 | $8K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 32 | $8K |
| 29515 | <1% | 28 | $7K | |
| 71250 | <1% | 62 | $7K | |
| 74174 | <1% | 24 | $7K | |
| 81001 | <1% | 16,747 | $7K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,254 | $7K |
| 87486 | <1% | 259 | $6K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 831 | $6K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,930 | $6K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,384 | $6K |
| C9399 | Unclassified drugs or biologicals | <1% | 150 | $6K |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | <1% | 53 | $6K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,310 | $6K |
| 97010 | <1% | 530 | $6K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,658 | $5K |
| 87581 | <1% | 257 | $5K | |
| 86769 | <1% | 381 | $5K | |
| 87641 | <1% | 132 | $4K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,887 | $4K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 930 | $4K |
| 70496 | <1% | 234 | $4K | |
| 93017 | <1% | 76 | $4K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,663 | $4K |
| 83735 | <1% | 5,475 | $4K | |
| 84484 | <1% | 10,273 | $4K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,064 | $4K |
| 59050 | <1% | 14 | $4K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,339 | $4K |
| 75574 | <1% | 14 | $4K | |
| 82962 | <1% | 7,689 | $3K | |
| 83690 | <1% | 11,668 | $3K | |
| 73610 | <1% | 1,364 | $3K | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 85 | $3K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,179 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,683 | $2K |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 115 | $2K |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 472 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,088 | $2K |
| 85379 | <1% | 2,643 | $2K | |
| 36000 | <1% | 65 | $2K | |
| 88304 | <1% | 84 | $2K | |
| 83605 | <1% | 4,534 | $2K | |
| 73630 | <1% | 1,311 | $2K | |
| 97163 | <1% | 14 | $2K | |
| J7324 | Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose | <1% | 20 | $2K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,667 | $1K |
| 73130 | <1% | 1,348 | $1K | |
| 87040 | <1% | 1,788 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,184 | $1K |
| 84100 | <1% | 917 | $1K | |
| 81003 | <1% | 3,647 | $1K | |
| 73110 | <1% | 730 | $1K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 28 | $996.30 |
| 73030 | <1% | 1,047 | $987.05 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 375 | $828.67 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 942 | $816.99 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 37 | $813.95 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 98 | $745.61 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 160 | $736.04 |
| 73564 | <1% | 576 | $733.32 | |
| 82728 | <1% | 227 | $730.34 | |
| 80061 | Lipid panel | <1% | 65 | $726.78 |
| 87186 | <1% | 1,649 | $546.98 | |
| 73562 | <1% | 498 | $544.81 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 478 | $525.84 |
| 73590 | <1% | 361 | $524.56 | |
| J0574 | Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine | <1% | 65 | $487.60 |
| 64484 | <1% | 12 | $448.08 | |
| 82330 | <1% | 1,681 | $422.28 | |
| 84436 | <1% | 1,079 | $406.12 | |
| 87077 | <1% | 916 | $403.99 | |
| 82550 | <1% | 1,789 | $344.44 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 46 | $332.46 |
| 84132 | <1% | 1,582 | $322.29 | |
| 84295 | <1% | 1,522 | $293.40 | |
| 82435 | <1% | 1,519 | $274.79 | |
| 87640 | <1% | 136 | $274.67 | |
| 87800 | <1% | 13 | $253.15 | |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 17 | $248.91 |
| 82947 | <1% | 1,525 | $246.80 | |
| 86140 | <1% | 634 | $240.73 | |
| 73090 | <1% | 246 | $224.90 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 75 | $217.89 |
| 87070 | <1% | 70 | $150.18 | |
| 84480 | <1% | 280 | $139.29 | |
| 85014 | <1% | 1,540 | $139.02 | |
| 84466 | <1% | 14 | $137.31 | |
| 85018 | <1% | 1,493 | $135.36 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 218 | $119.23 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 31 | $114.19 |
| 85652 | <1% | 303 | $113.82 | |
| 84145 | <1% | 89 | $111.73 | |
| 86803 | <1% | 186 | $94.80 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 17 | $88.04 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 188 | $85.85 |
| 82553 | <1% | 448 | $65.28 | |
| 83540 | <1% | 14 | $55.25 | |
| 85384 | <1% | 29 | $54.09 | |
| 83615 | <1% | 44 | $43.62 | |
| 86780 | <1% | 47 | $37.30 | |
| 87081 | <1% | 198 | $32.73 | |
| 76870 | <1% | 16 | $30.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 12 | $26.50 |
| 73080 | <1% | 128 | $25.00 | |
| 82009 | <1% | 110 | $17.52 | |
| 73502 | <1% | 13 | $12.47 | |
| 74018 | <1% | 39 | $10.00 | |
| 99080 | 0% | 3,388 | $0.00 | |
| 73140 | 0% | 13 | $0.00 | |
| 99152 | 0% | 15 | $0.00 | |
| 84550 | 0% | 15 | $0.00 | |
| 83986 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCUSACK, MICHELE (SENIOR VICE PRESIDENT & CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.